Press release
Lawsuit filed for Investors in shares of Amarin Corporation plc (NASDAQ: AMRN)
An investor, who purchased shares of Amarin Corporation plc (NASDAQ: AMRN), filed a lawsuit in the over alleged violations of Federal Securities Laws by Amarin Corporation plc.
Investors who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2021. NASDAQ: AMRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Ireland based Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.
Amarin lead product since 2008 is Vascepa®, a prescription grade ultra-pure omega-3 fatty acid derived from fish oil.
On March 30, 2020, Amarin Corporation plc announced that the United States District Court for the District of Nevada had "rul[ed] in favor of the generic companies in the company’s patent litigation against two filers of ... ANDA s ... for Amarin’s VASCEPA® (icosapent ethyl) capsule franchise."
On September 2, 2020, as the Court of Appeals for the Federal Circuit heard oral arguments for Amarin’s patent litigation, and the next day, affirmed the District Court’s ruling.
Then, on April 12, 2021, Amarin Corporation plc announced the retirement of John F. Thero, the Company’s President and CEO.
Finally, on June 21, 2021, investors learned "that the Supreme Court rejected the [C]ompany’s bid to revive Vascepa® patents."
Shares of Amarin Corporation plc (NASDAQ: AMRN) declinedfrom over $24.00 per share in December 2019, to as low as $3.84 per share on July 27, 2021.
According to the complaint the plaintiff alleges on behalf of purchasers of Amarin Corporation plc (NASDAQ: AMRN) common shares between December 5, 2018, and June 21, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 5, 2018, and June 21, 2021, the Defendants made false and misleading statements and/or failed to disclose that there was an increasingly high risk that certain of Amarin’s patents would be invalidated, that once certain of Amarin’s patents were invalidated by the United States District Court for the District of Nevada, there was little to no chance of reversing that ruling, that the Company’s litigation was preventing it from effectuating a successful takeover, that Defendants were downplaying the true threat the ongoing Abbreviated New Drug Application ("ANDA") litigation posed to the Company’s business and future prospects, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Investors who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2021. NASDAQ: AMRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Ireland based Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.
Amarin lead product since 2008 is Vascepa®, a prescription grade ultra-pure omega-3 fatty acid derived from fish oil.
On March 30, 2020, Amarin Corporation plc announced that the United States District Court for the District of Nevada had "rul[ed] in favor of the generic companies in the company’s patent litigation against two filers of ... ANDA s ... for Amarin’s VASCEPA® (icosapent ethyl) capsule franchise."
On September 2, 2020, as the Court of Appeals for the Federal Circuit heard oral arguments for Amarin’s patent litigation, and the next day, affirmed the District Court’s ruling.
Then, on April 12, 2021, Amarin Corporation plc announced the retirement of John F. Thero, the Company’s President and CEO.
Finally, on June 21, 2021, investors learned "that the Supreme Court rejected the [C]ompany’s bid to revive Vascepa® patents."
Shares of Amarin Corporation plc (NASDAQ: AMRN) declinedfrom over $24.00 per share in December 2019, to as low as $3.84 per share on July 27, 2021.
According to the complaint the plaintiff alleges on behalf of purchasers of Amarin Corporation plc (NASDAQ: AMRN) common shares between December 5, 2018, and June 21, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 5, 2018, and June 21, 2021, the Defendants made false and misleading statements and/or failed to disclose that there was an increasingly high risk that certain of Amarin’s patents would be invalidated, that once certain of Amarin’s patents were invalidated by the United States District Court for the District of Nevada, there was little to no chance of reversing that ruling, that the Company’s litigation was preventing it from effectuating a successful takeover, that Defendants were downplaying the true threat the ongoing Abbreviated New Drug Application ("ANDA") litigation posed to the Company’s business and future prospects, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
